静脈血栓塞栓症の世界市場レポート 2024年

静脈血栓塞栓症の市場規模は近年着実に成長しています。2023年の23億3,000万米ドルから2024年には24億4,000万米ドルへ、CAGR4.8％で拡大します。実績期間の成長は、高齢化、抗凝固薬の進歩、償還政策、投資の増加に起因しています。

静脈血栓塞栓症の市場規模は、今後数年間で安定した成長が見込まれます。2028年にはCAGR4.2％で28億7,000万米ドルに成長します。予測期間の成長は、世界のヘルスケアアクセス、遺伝リスク評価、遠隔医療と遠隔モニタリング、患者教育とサポートに起因します。予測期間の主な動向には、血栓予防の拡大、新規経口抗凝固薬、個別化治療計画、高度画像診断などが含まれます。

静脈血栓塞栓症市場の成長が期待される背景には、ヘルスケアインフラの拡大があります。ヘルスケア産業は、患者の治療、予防、リハビリテーション、緩和ケアのための製品やサービスを提供するさまざまなセクターの集合体です。このような拡大は、VTE予防プロトコルの効果的な実行を支援するために必要な機関インフラの整備、政策と実践の実施、および教育イニシアチブを促進します。例えば、米国医療協会によると、2023年5月、米国の病院数は2022年の6,093から6,129に増加しました。さらに、Office for National Statisticsの報告によると、英国のヘルスケア支出は2020年から2021年にかけて名目で9.4％、実質で9.7％と大幅に増加しました。その結果、ヘルスケア産業の成長が静脈血栓塞栓症市場拡大の原動力となっています。

静脈血栓塞栓症市場の成長をさらに後押ししているのが、整形外科手術の急増です。整形外科的処置は、脊椎、関節、骨格の変形に影響を及ぼす状態に対処するために使用される様々な外科的介入を包含します。人工膝関節全置換術（TKA）、人工股関節全置換術（THA）、股関節骨折手術（HFS）などの手術はVTEリスクの高まりと関連しているため、DVT予防のための圧迫器具の採用が増加しています。圧迫具は下肢の深部静脈に血栓が形成されるのを防ぎ、静脈血栓塞栓症（VTE）のリスクを軽減します。例えば、2023年2月にNational Library of Medicineが発表した調査によると、THAとTKAの手術件数は大幅に増加し、2040年までにそれぞれ1,222,988件、719,364件になると予測されています。さらに、TKAは2060年までに2,917,959件に達し、THAは1,982,099件になると予測されています。その結果、整形外科手術件数の増加が静脈血栓塞栓症市場の成長促進要因となっています。

2023年の静脈血栓塞栓症市場で最大の地域は北米でした。静脈血栓塞栓症レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の静脈血栓塞栓症市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 深部静脈血栓症
• 肺塞栓症
• その他のタイプ
• 世界の静脈血栓塞栓症市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 抗凝固薬
• 機械装置
• 血栓溶解療法
• その他の治療
• 世界の静脈血栓塞栓症市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 在宅ケア
• 専門センター
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の静脈血栓塞栓症市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の静脈血栓塞栓症市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 静脈血栓塞栓症市場の競合情勢
• 静脈血栓塞栓症市場の企業プロファイル
  • Pfizer Inc.
  • Johnson and Johnson Limited
  • Merck and Co. Inc.
  • AbbVie Inc.
  • Bayer AG

第31章 その他の主要および革新的な企業

• Novartis AG
• Sanofi-Aventis LLC.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Eli Lilly and Co Ltd.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Limited
• Otsuka Pharmaceutical Co. Ltd.
• Menarini Group
• Ipsen S.A.
• Dr. Reddy's Laboratories Ltd.
• Apotex Inc.
• Hikma Pharmaceuticals PLC

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Venous Thromboembolism Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on venous thromboembolism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for venous thromboembolism? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The venous thromboembolism market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Deep Vein Thrombosis; Pulmonary Embolism; Other Types
• 2) By Treatment: Anti-Clotting Medications; Mechanical Devices; Thrombolytic Therapy; Other Treatment
• 3) By End Users: Hospitals; Homecare; Specialty Centers; Other End Users
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; Merck and Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Venous thromboembolism (VTE) is a medical condition marked by the development of blood clots within the veins, carrying the potential for serious or life-threatening complications. Common indicators of VTE encompass symptoms like leg pain and swelling, rapid breathing, chest discomfort, and more. Diverse treatment methods, including anticoagulant medications, medical devices, and thrombolytic therapy, are employed in managing VTE.

The primary categories of venous thromboembolism consist of deep vein thrombosis, pulmonary embolism, and other related conditions. Deep vein thrombosis (DVT) represents a medical condition characterized by the development of blood clots within the deep veins of the body. Treatment options encompass the use of anticoagulant medications, mechanical devices, thrombolytic therapy, and various other interventions. These treatments cater to diverse end-users, including hospitals, homecare settings, specialty centers, and other relevant healthcare facilities.

The venous thromboembolism market research report is one of a series of new reports from The Business Research Company that provides venous thromboembolism market statistics, including venous thromboembolism industry global market size, regional shares, competitors with a venous thromboembolism market share, detailed venous thromboembolism market segments, market trends and opportunities and any further data you may need to thrive in the venous thromboembolism industry. This venous thromboembolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The venous thromboembolism market size has grown steadily in recent years. It will grow from $2.33 billion in 2023 to $2.44 billion in 2024 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to aging population, advancements in anticoagulants, reimbursement policies, increasing investments.

The venous thromboembolism market size is expected to see steady growth in the next few years. It will grow to $2.87 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to global healthcare access, genetic risk assessment, telemedicine and remote monitoring, patient education and support. Major trends in the forecast period include extended thromboprophylaxis, novel oral anticoagulants, personalized treatment plans, advanced diagnostic imaging.

The anticipated growth in the venous thromboembolism market is underpinned by the expansion of healthcare infrastructure. The healthcare industry encompasses the amalgamation of various sectors dedicated to offering products and services for patient treatment, prevention, rehabilitation, and palliative care. This expansion facilitates the development of institutional infrastructure, the implementation of policies and practices, and educational initiatives necessary for supporting the effective execution of VTE prevention protocols. For instance, in May 2023, the number of hospitals in the US increased to 6,129 from 6,093 in 2022, according to the American Health Care Association. Moreover, healthcare spending in the UK saw a significant increase of 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021, as reported by the Office for National Statistics. Consequently, the growth of the healthcare industry is a driving force behind the venous thromboembolism market's expansion.

The growth of the venous thromboembolism market is further bolstered by the escalating number of orthopedic procedures. Orthopedic procedures encompass various surgical interventions used to address conditions affecting the spine, joints, and skeletal deformities. Procedures like total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS) are associated with a heightened risk of VTE, leading to an increased adoption of compression devices for DVT prophylaxis. Compression devices serve to prevent the formation of blood clots in the deep veins of the legs, mitigating the risk of venous thromboembolism (VTE). For instance, research published by the National Library of Medicine in February 2023 indicates that THA and TKA procedures are projected to rise significantly, with 1,222,988 and 719,364 procedures, respectively, anticipated by 2040. Moreover, TKAs are estimated to reach 2,917,959 by 2060, while THAs are projected to total 1,982,099 by that time. Consequently, the mounting number of orthopedic procedures is a significant driver of the venous thromboembolism market's growth.

The venous thromboembolism market faces the restraint of high research and development costs, potentially hindering its future growth. The costs associated with VTE treatment can be substantial, limiting accessibility for certain patients. This is particularly relevant for newer treatments like novel oral anticoagulants (NOACs), which can be pricier than traditional anticoagulants. As per an article published in Springer, recent analyses indicate that the average cost of a VTE event varies between $12,000 and $15,000 per patient, resulting in an annual projected healthcare system cost of $7-10 billion in the United States. Consequently, the substantial treatment costs serve as a significant restraint on the venous thromboembolism market.

Leading companies within the venous thromboembolism market are spearheading the development of innovative anticoagulant drugs and solutions to maintain their market positions. Advances in anticoagulants hold the potential to yield more effective drugs capable of preventing or treating venous thromboembolism. For example, in September 2022, Anthos Therapeutics, a US-based clinical-stage biotherapeutics company, secured regulatory approval for its abelacimab anticoagulant medication from the Food and Drug Administration (FDA). This fully human monoclonal antibody is indicated for stroke and systemic embolism prevention in atrial fibrillation patients. The newly developed abelacimab, a once-monthly dual-acting antibody, is designed to provide hemostasis-sparing anticoagulation by inhibiting Factor XI.

In July 2021, Surmodics Inc., a US-based surface modification technologies manufacturer, acquired Vetex Medical Limited. The acquisition aims to expand Surmodics' thrombectomy portfolio, introducing the ReVene Thrombectomy Catheter to its product offerings. Vetex Medical Limited, based in Ireland, specializes in devices for venous thromboembolism (VTE) and other medical conditions.

Major players in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

North America was the largest region in the venous thromboembolism market in 2023. The regions covered in venous thromboembolism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the venous thromboembolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The venous thromboembolism market consists of revenues earned by entities by providing services such as surgical assistance and thrombolytic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The venous thromboembolism market also includes the sales of heparin, apixaban, dabigatran, rivaroxaban, edoxaban and warfarin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Venous Thromboembolism Market Characteristics

3. Venous Thromboembolism Market Trends And Strategies

4. Venous Thromboembolism Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Venous Thromboembolism Market Size and Growth

• 5.1. Global Venous Thromboembolism Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Venous Thromboembolism Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Venous Thromboembolism Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Venous Thromboembolism Market Segmentation

• 6.1. Global Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Deep Vein Thrombosis
• Pulmonary Embolism
• Other Types
• 6.2. Global Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Anti-Clotting Medications
• Mechanical Devices
• Thrombolytic Therapy
• Other Treatment
• 6.3. Global Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Homecare
• Speciality Centres
• Other End Users

7. Venous Thromboembolism Market Regional And Country Analysis

• 7.1. Global Venous Thromboembolism Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Venous Thromboembolism Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Venous Thromboembolism Market

• 8.1. Asia-Pacific Venous Thromboembolism Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Venous Thromboembolism Market

• 9.1. China Venous Thromboembolism Market Overview
• 9.2. China Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Venous Thromboembolism Market

• 10.1. India Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Venous Thromboembolism Market

• 11.1. Japan Venous Thromboembolism Market Overview
• 11.2. Japan Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Venous Thromboembolism Market

• 12.1. Australia Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Venous Thromboembolism Market

• 13.1. Indonesia Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Venous Thromboembolism Market

• 14.1. South Korea Venous Thromboembolism Market Overview
• 14.2. South Korea Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Venous Thromboembolism Market

• 15.1. Western Europe Venous Thromboembolism Market Overview
• 15.2. Western Europe Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Venous Thromboembolism Market

• 16.1. UK Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Venous Thromboembolism Market

• 17.1. Germany Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Venous Thromboembolism Market

• 18.1. France Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Venous Thromboembolism Market

• 19.1. Italy Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Venous Thromboembolism Market

• 20.1. Spain Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Venous Thromboembolism Market

• 21.1. Eastern Europe Venous Thromboembolism Market Overview
• 21.2. Eastern Europe Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Venous Thromboembolism Market

• 22.1. Russia Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Venous Thromboembolism Market

• 23.1. North America Venous Thromboembolism Market Overview
• 23.2. North America Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Venous Thromboembolism Market

• 24.1. USA Venous Thromboembolism Market Overview
• 24.2. USA Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Venous Thromboembolism Market

• 25.1. Canada Venous Thromboembolism Market Overview
• 25.2. Canada Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Venous Thromboembolism Market

• 26.1. South America Venous Thromboembolism Market Overview
• 26.2. South America Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Venous Thromboembolism Market

• 27.1. Brazil Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Venous Thromboembolism Market

• 28.1. Middle East Venous Thromboembolism Market Overview
• 28.2. Middle East Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Venous Thromboembolism Market

• 29.1. Africa Venous Thromboembolism Market Overview
• 29.2. Africa Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Venous Thromboembolism Market Competitive Landscape And Company Profiles

• 30.1. Venous Thromboembolism Market Competitive Landscape
• 30.2. Venous Thromboembolism Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson and Johnson Limited
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck and Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AbbVie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Venous Thromboembolism Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi-Aventis LLC.
• 31.3. Bristol-Myers Squibb Company
• 31.4. GlaxoSmithKline plc.
• 31.5. Eli Lilly and Co Ltd.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Daiichi Sankyo Company Limited
• 31.9. Sun Pharmaceutical Industries Limited
• 31.10. Otsuka Pharmaceutical Co. Ltd.
• 31.11. Menarini Group
• 31.12. Ipsen S.A.
• 31.13. Dr. Reddy's Laboratories Ltd.
• 31.14. Apotex Inc.
• 31.15. Hikma Pharmaceuticals PLC

32. Global Venous Thromboembolism Market Competitive Benchmarking

33. Global Venous Thromboembolism Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Venous Thromboembolism Market

35. Venous Thromboembolism Market Future Outlook and Potential Analysis

• 35.1 Venous Thromboembolism Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Venous Thromboembolism Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Venous Thromboembolism Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer